Table 2. Changes in migraine characteristics from the BL to the FUP.
| BL | FUP | |
|---|---|---|
| Age, years | 10.2±2.9 | 12.3±2.7 |
| Diagnosis | ||
| Migraine without aura | 14 (77.8) | 13 (72.2) |
| Migraine with aura | 4 (22.2) | 5 (27.8) |
| Aura | ||
| Visual | 5 (27.8) | 5 (27.8) |
| Sensory | 2 (11.1) | 0 (0) |
| Pain quality | ||
| Throbbing | 9 (50.0) | 9 (50.0) |
| Compressive | 11 (61.1) | 10 (55.6) |
| Explosive | 2 (11.1) | 4 (22.2) |
| Implosive | 1 (5.6) | 0 (0) |
| Others | 2 (11.1) | 2 (11.1) |
| Pain location | ||
| Unilateral | 8 (44.4) | 6 (33.3) |
| Bilateral | 10 (55.6) | 12 (66.7) |
| Attack duration | ||
| <4 hours | 0 (0.0) | 4 (22.2) |
| 4–24 hours | 13 (72.2) | 9 (50.0) |
| 25–48 hours | 2 (11.1) | 4 (22.2) |
| 49–72 hours | 2 (11.1) | 1 (5.6) |
| >72 hours | 1 (5.6) | 0 (0.0) |
| Monthly attack frequency | ||
| <3 attacks | 10 (55.6) | 9 (50.0) |
| 3–6 attacks | 5 (27.8) | 7 (38.9) |
| 6–10 attacks | 1 (5.6) | 2 (11.1) |
| >10 attacks | 1 (5.6) | 0 (0.0) |
| Symptomatic medication use and response | ||
| NSAIDs | 18 (100.0) | 15 (83.3) |
| NSAIDs improvement | 15 (83.3) | 15 (83.3) |
| Simple analgesics | 6 (33.3) | 12 (66.7) |
| Simple analgesics improvement | 4 (22.3) | 10 (55.5) |
| Triptans | 0 (0.0) | 2 (11.1) |
| Triptans improvement | 0 (0.0) | 2 (11.1) |
| Preventive treatment | ||
| Ongoing | 4 (22.3) | 2 (11.1) |
| Past | 3 (16.7) | 5 (27.8) |
| PedMIDAS disability | ||
| Little or none | 7 (38.9) | 5 (27.8) |
| Mild | 7 (38.9) | 9 (50.0) |
| Moderate | 2 (11.1) | 3 (16.7) |
| Severe | 2 (11.1) | 1 (5.6) |
Data are mean±SD or n (%) values. No significant changes were found in these characteristics.
BL: baseline visit, FUP: follow-up visit, NSAIDs: nonsteroidal anti-inflammatory drugs, PedMIDAS: Pediatric Migraine Disability Assessment Score.